在淋巴浆细胞淋巴瘤/华氏巨球蛋白血症及其他B细胞非霍奇金淋巴瘤患者中检测MYD88 L265P
Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.
作者信息
Shin Sang-Yong, Lee Seung-Tae, Kim Hyun-Young, Park Chang-Hun, Kim Hee-Jin, Kim Jong-Won, Kim Seok Jin, Kim Won Seog, Kim Sun-Hee
机构信息
Department of Laboratory Medicine, Center for Diagnostic Oncology, Hospital and Research Institute, National Cancer Center, Goyang, Korea.
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Blood Res. 2016 Sep;51(3):181-186. doi: 10.5045/br.2016.51.3.181. Epub 2016 Sep 23.
BACKGROUND
Recent studies have identified a high prevalence of the L265P mutation in lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM) cases, whereas low frequencies have been observed in other B cell non-Hodgkin lymphomas (NHLs).
METHODS
We evaluated the sensitivity of the mutant enrichment 3'-modified oligonucleotide (MEMO)-PCR technique, a new detection method. We examined the L265P mutation in a series of Korean patients with LPL/WM and other B cell NHLs in bone marrow aspirates, using the MEMO-PCR technique.
RESULTS
The sensitivity of MEMO-PCR was estimated to be approximately 10-16.7%. L265P was detected in 21 of 28 LPL cases (75%) and only three of 69 B cell NHL cases (4.3%).
CONCLUSION
Although MEMO-PCR had relatively low sensitivity, we confirmed the high prevalence of the L265P mutation in Korean LPL patients. Our study suggests the diagnostic value of L265P for differentiating B-cell NHLs.
背景
近期研究发现，L265P突变在淋巴浆细胞淋巴瘤（LPL）/华氏巨球蛋白血症（WM）病例中普遍存在，而在其他B细胞非霍奇金淋巴瘤（NHL）中发生率较低。
方法
我们评估了一种新的检测方法——突变富集3'-修饰寡核苷酸（MEMO）-PCR技术的敏感性。我们使用MEMO-PCR技术检测了一系列韩国LPL/WM患者及其他B细胞NHL患者骨髓穿刺液中的L265P突变。
结果
MEMO-PCR的敏感性估计约为10-16.7%。28例LPL病例中有21例（75%）检测到L265P突变，而69例B细胞NHL病例中仅3例（4.3%）检测到该突变。
结论
尽管MEMO-PCR的敏感性相对较低，但我们证实了韩国LPL患者中L265P突变的高发生率。我们的研究表明L265P对鉴别B细胞NHL具有诊断价值。
Zotero 插件